Palliative care access to core medicines (extended program)

Active
Duration:

15 September 2023 – Ongoing

Funding Amount:

$70,000 (ex GST)

Locations

all

Melbourne Macedon Ranges Yarra Moonee Valley Darebin Maribyrnong Hobsons Bay Wyndham Brimbank Moorabool Melton Hume Merri-bek

Overview

The Palliative Care Access to Core Medicines (PCAM) project supports palliative care in the community by increasing access to essential medicines for people who wish to die at home or in an aged care setting.

The project recruits community pharmacies, which agree to stock the medications most commonly prescribed to control symptoms experienced by people in the final period of their lives. Doing so eases access to these vital medicines, making the process of acquiring them simpler for the families and carers of the dying, as well as reducing discomfort and suffering.

The medications stocked comprise the Core Medicines List, which was drawn up after consultation with palliative care experts. Participating pharmacies are displayed on a PCAM-specific map, allowing prescribers, patients and carers to quickly locate the most convenient supplier.

PCAM began in 2021, with North Western Melbourne Primary Health Network (NWMPHN) operating in concert with the Pharmaceutical Society of Australia (PSA).

It was extended in 2023, with Eastern Melbourne Primary Health Network (EMPHN) and South Eastern Melbourne Primary Health Network (SEMPHN) joining. At the same time, given that the project had reached a level of maturity, PSA ceased active involvement.

By mid-2024 more than 300 pharmacies across the metropolitan area had signed up to PCAM, including 111 in the NWMPHN catchment. Recruitment continues. You can apply here.

The Core Medicines List for community palliative care patients

Medicine Category First Line Medicines Minimum Quantity to stock Indication/(s) for use in terminal phase patients
Anxiolytic

 

 

 

Clonazepam 2.5mg/mL (0.1mg/drop) Oral Liquid

 

Midazolam 5mg/mL Injection

(If an injection is required or preferred)

10mL bottle

 

 

5 or 10 ampoules

 

Agitation associated with delirium

Anxiety associated with dyspnoea

Antipsychotic Haloperidol 5mg/mL Injection 10 ampoules

 

Agitation

Nausea, vomiting

 

Anticholinergic Hyoscine butylbromide 20mg/mL Injection 5 ampoules

 

Respiratory tract secretions

Noisy breathing

Antiemetic Metoclopramide 10mg/2mL Injection 10 ampoules Nausea, vomiting
Analgesic

(High potency opioid)

Morphine (sulfate or hydrochloride) 10mg/mL and/or 30mg/mL Injection 5 ampoules Dyspnoea

Pain

Outcomes

The project:

  • Increases awareness and usage of the CML and pharmacy locator map.
  • Preserves the number of community pharmacies stocking all medicines on the CML.
  • Ensures all information on the CML is up to date.
  • Facilitates data-sharing to sustain the pharmacy locator map.

Services involved